The Global Acute Intermittent Porphyria industry is projected to grow from USD 4.61 Billion in 2024 to USD 7.34 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.90% during the forecast period (2024 - 2032).
The risk factors associated with acute intermittent porphyria, which include liver cancer (hepatocellular carcinoma), kidney failure, neurological disorders, psychiatric...
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek